ClinicalTrials.gg
CompletedNCT02334800Updated Jan 24, 2018Results posted

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

A Phase 1 interventional study of Palbociclib 75 mg Capsule in Healthy, Hepatic Insufficiency, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.

Enrollment
24th of 48
28 · median 28
Started
2015
with 2 others
Phase 1
42 of 52
3 open now
Registered
23rd of 52
by date
Lead sponsor
5 of 52
Pfizer

Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 24th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2015, is one of 42 in phase 1, and was the 23rd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of palbociclib administered to healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function.

Read the detailed description

This is a 4-cohort single period study. The four cohorts will consist of healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function. Each cohort will receive the same treatment consisting of a single oral 75mg dose of palbociclib administered with food. Serial PK samples will be drawn up to 120 hours post dose for the cohort consisting of healthy volunteers, and will continue until up to 192 hours post-dose for the cohorts of hepatic impairment subjects.

03

Conditions studied

  • Healthy, Hepatic Insufficiency

Browse trials for

Keywords

  • Palbociclib, PD-0332991, Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18 to 40 kg/m2; and a total body weight >50 kg (110 lbs)
  • Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study
  • Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption (eg, gastrectomy)
  • A positive urine drug screen
  • Pregnant female subjects; breastfeeding female subjects; female subjects of ; male subjects with partners currently pregnant; male subjects of childbearing potential who are unwilling or unable to use a highly effective method of for the duration of the study and for 90 days after the last dose of product
  • History of sensitivity to heparin or heparin-induced thrombocytopenia
  • Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to dosing
  • Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol
  • Use of tobacco or nicotine products in excess of 5 cigarettes per day (or equivalent)
  • History of sensitivity to palbociclib
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Healthy Volunteers

    Cohort of Healthy Volunteers

    Drug: Palbociclib 75 mg Capsule

  • Experimental
    Mild Hepatic Impairment

    Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A

    Drug: Palbociclib 75 mg Capsule

  • Experimental
    Moderate Hepatic Impairment

    Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B

    Drug: Palbociclib 75 mg Capsule

  • Experimental
    Severe Hepatic Impairment

    Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C

    Drug: Palbociclib 75 mg Capsule

Interventions

  • Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).

    Also known as: Palbociclib, PD-0332991

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)

    AUCinf is area under the plasma concentration time curve from time 0 extrapolated infinite time. It is calculated as AUClast + (Clast/kel), where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration, Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  2. Maximum Plasma Concentration (Cmax)

    Cmax is maximum plasma concentration. It is observed directly from data.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

Secondary outcomes

  1. Unbound AUCinf (AUCinf,u)

    AUCinf,u is unbound AUCinf, where AUCinf is area under the concentration-time curve from time 0 extrapolated to infinite time. It is obtained by fu\*AUCinf, where fu is the fraction of unbound drug in plasma.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  2. Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

    AUClast is area under the plasma concentration time curve from time 0 to time of last quantifiable concentration. It is obtained from linear/log trapezoidal method.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  3. Unbound AUClast (AUClast,u)

    AUClast,u is unbound AUClast, where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. It is obtained by fu\*AUClast, where fu is the fraction of unbound drug in plasma.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  4. Apparent Clearance After Oral Dose(CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance is obtained by dose/AUCinf, where AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  5. Unbound CL/F (CLu/F)

    CLu/F is unbound CL/F, where CL/F is apparent clearance after oral dose. It is obtained by dose/AUCinf,u, where AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  6. Unbound Cmax (Cmax,u)

    Cmax,u is unbound Cmax, where Cmax is maximum plasma concentration. It is obtained by fu\*Cmax, where fu is fraction of unbound drug in plasma.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  7. Fraction of Unbound Drug in Plasma (fu)

    Fu is the fraction of unbound drug in plasma. It is obtained from measurement of protein binding.

    Time frame: Eight (8) hours post-dose.

  8. Terminal Half-Life (t1/2)

    T1/2 is terminal half-life. It is obtained by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  9. Time for Cmax (Tmax)

    Tmax is time for maximum plasma concentration. It is observed directly from data as time of first occurrence of maximum plasma concentration.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  10. Apparent Volunm of Distribution After Oral Dose (Vz/F)

    Vz/F is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. It is influenced by the fraction absorbed. It is obtained by dose/(AUCinf•kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.

    Time frame: pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  11. Unbound Vz/F (Vz,u/F)

    Vz,u/F is unbound Vz/F, where Vz/F is apparent volume of distribution after oral dose. It is obtained by dose/(AUCinf,u\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.

  12. Number of Participants With Treatment Emergent Adverse Events

    An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

    Time frame: Adverse events were recorded on the Case Report Form from the time the participant had taken at least 1 dose of palbociclib through the participant's last visit.

  13. Number of Participants With Treatment Emergent Serious Adverse Events

    A serious adverse event is any untoward medical occurrence at any dose that resulted in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; or results in congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No).

    Time frame: The active reporting period for serious adverse events began from the time that the participant provided informed consent through and including 28 calendar days after the last administration of palbociclib.

  14. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.

    Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, inclusive of baseline values.

  15. Number of Participants With Physical Examination Test Abnormalities (Change From Prior Visit)

    A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.

    Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4.

  16. Number of Participants With Post Baseline Vital Signs Values Meeting Categorical Summarization Criteria

    The number of participants with post baseline vital signs values meeting the following criteria was reported: A. absolute value of supine systolic blood pressure less than (\<) 90 mmHg; B. absolute value of diastolic blood pressure \<50 mmHg; C. absolute value of supine pulse rate \<40 bmp; D. absolute value of supine pulse rate larger than (\>) 120 bmp; E. maximum increase from baseline in supine systolic blood pressure larger than and equal to (\>=) 30 mmHg; F. maximum increase from baseline in supine diastolic blood pressure \>=20 mmHg; G. maximum decrease from baseline in supine systolic blood pressure \>=30 mmHg; and H. maximum decrease from baseline in supine diastolic blood pressure \>=20 mmHg.

    Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.

  17. Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Absolute Values)

    Maximum absolute values of post baseline electrocardiogram were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum absolute values of post baseline electrocardiogram meeting the following criteria was reported: (1) PR interval \>=300 msec; (2) QRS complex \>=140 msec; (3) QT interval 450 to \<480 msec; (4) QT interval 480 to \<500 msec; (5) QT interval \>= 500 msec; (6) QTcB 450 to \<480 msec; (7) QTcB 480 to \<500 msec; (8) QTcB \>= 500 msec; (9) QTcF 450 to \<480 msec; (10) QTcF 480 to \<500 msec; and (11) QTcF \>=500 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.

    Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.

  18. Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Increase From Baseline)

    Maximum increases from baseline for post baseline electrocardiogram values were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum increase from baseline for post baseline electrocardiogram values meeting the following criteria was reported: (1) percent change of PR interval \>=25/50%; (2) percent change of QRS complex \>=50%; (3) QT interval 30 to \<60 msec; (4) QT interval \>= 60 msec; (5) QTcB 30 to \<60 msec; (6) QTcB \>= 60 msec; (7) QTcF 30 to \<60 msec; and (8) QTcF \>= 60 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.

    Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.

  19. Number of Participants With Concomitant Medications

    Treatments taken after the first dose of study treatment were documented as concomitant treatments.

    Time frame: From screening through and including Day 6 for Cohort 1, and from screening through and including Day 9 for Cohorts 2, 3, and 4.

07

Results

Posted Jan 24, 2018

Participant flow

Participant flow — Overall Study
MilestonePalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Started7777
Received treatment7777
Completed7777
Not completed0000

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)

AUCinf is area under the plasma concentration time curve from time 0 extrapolated infinite time. It is calculated as AUClast + (Clast/kel), where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration, Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)
nanogram*hour/milliliter (ng*hr/mL)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)1031 ± 24758.9 ± 311189 ± 221378 ± 29
Statistical analysis
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) · Ratio of adjusted geometric mean: 73.60 · 90% CI 57.81 to 93.71
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) · Ratio of adjusted geometric mean: 115.30 · 90% CI 90.57 to 146.79
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) · Ratio of adjusted geometric mean: 133.68 · 90% CI 105.00 to 170.19
PrimaryMaximum Plasma Concentration (Cmax)

Cmax is maximum plasma concentration. It is observed directly from data.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Plasma Concentration (Cmax)
nanogram/milliliter (ng/mL)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Maximum Plasma Concentration (Cmax)28.64 ± 2027.20 ± 3733.72 ± 2837.20 ± 48
Statistical analysis
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) · Ratio of adjusted geometric mean: 94.99 · 90% CI 69.93 to 129.03
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) · Ratio of adjusted geometric mean: 117.75 · 90% CI 86.69 to 159.95
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) · Ratio of adjusted geometric mean: 129.89 · 90% CI 95.63 to 176.43
SecondaryUnbound AUCinf (AUCinf,u)

AUCinf,u is unbound AUCinf, where AUCinf is area under the concentration-time curve from time 0 extrapolated to infinite time. It is obtained by fu\*AUCinf, where fu is the fraction of unbound drug in plasma.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · ng*hr/mL
Unbound AUCinf (AUCinf,u)
ng*hr/mLPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Unbound AUCinf (AUCinf,u)196.6 ± 26163.2 ± 32264.1 ± 25347.8 ± 23
Statistical analysis
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) · Ratio of adjusted geometric mean: 83.01 · 90% CI 65.37 to 105.43
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) · Ratio of adjusted geometric mean: 134.28 · 90% CI 105.73 to 170.53
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) · Ratio of adjusted geometric mean: 176.88 · 90% CI 139.28 to 224.63
SecondaryArea Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

AUClast is area under the plasma concentration time curve from time 0 to time of last quantifiable concentration. It is obtained from linear/log trapezoidal method.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
ng*hr/mLPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)973.3 ± 24708.6 ± 341125 ± 241311 ± 31
Statistical analysis
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) · Ratio of adjusted geometric mean: 72.81 · 90% CI 56.43 to 93.93
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) · Ratio of adjusted geometric mean: 115.57 · 90% CI 89.58 to 149.11
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) · Ratio of adjusted geometric mean: 134.66 · 90% CI 104.38 to 173.73
SecondaryUnbound AUClast (AUClast,u)

AUClast,u is unbound AUClast, where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. It is obtained by fu\*AUClast, where fu is the fraction of unbound drug in plasma.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · ng*hr/mL
Unbound AUClast (AUClast,u)
ng*hr/mLPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Unbound AUClast (AUClast,u)185.5 ± 26152.4 ± 35250.3 ± 26331.0 ± 24
Statistical analysis
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) · Ratio of adjusted geometric mean: 82.14 · 90% CI 63.83 to 105.71
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) · Ratio of adjusted geometric mean: 134.90 · 90% CI 104.82 to 173.60
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) · Ratio of adjusted geometric mean: 178.39 · 90% CI 138.62 to 229.57
SecondaryApparent Clearance After Oral Dose(CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance is obtained by dose/AUCinf, where AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · liter/hour (L/hr)
Apparent Clearance After Oral Dose(CL/F)
liter/hour (L/hr)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Apparent Clearance After Oral Dose(CL/F)72.64 ± 2498.84 ± 3163.15 ± 2254.42 ± 29
SecondaryUnbound CL/F (CLu/F)

CLu/F is unbound CL/F, where CL/F is apparent clearance after oral dose. It is obtained by dose/AUCinf,u, where AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · L/hr
Unbound CL/F (CLu/F)
L/hrPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Unbound CL/F (CLu/F)381.3 ± 26459.2 ± 32283.8 ± 25215.8 ± 23
SecondaryUnbound Cmax (Cmax,u)

Cmax,u is unbound Cmax, where Cmax is maximum plasma concentration. It is obtained by fu\*Cmax, where fu is fraction of unbound drug in plasma.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · ng/mL
Unbound Cmax (Cmax,u)
ng/mLPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Unbound Cmax (Cmax,u)5.456 ± 235.858 ± 377.501 ± 349.399 ± 47
Statistical analysis
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) · Ratio of adjusted geometric mean: 107.37 · 90% CI 78.06 to 147.68
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) · Ratio of adjusted geometric mean: 137.50 · 90% CI 99.96 to 189.12
  • Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) vs Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) · Ratio of adjusted geometric mean: 172.27 · 90% CI 125.25 to 236.96
SecondaryFraction of Unbound Drug in Plasma (fu)

Fu is the fraction of unbound drug in plasma. It is obtained from measurement of protein binding.

Time frame:
Eight (8) hours post-dose.
Reported as:
Mean · ratio
Fraction of Unbound Drug in Plasma (fu)
ratioPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Fraction of Unbound Drug in Plasma (fu)0.1910 ± 0.0150.2157 ± 0.0140.2236 ± 0.0250.2546 ± 0.036
SecondaryTerminal Half-Life (t1/2)

T1/2 is terminal half-life. It is obtained by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Mean · hour (hr)
Terminal Half-Life (t1/2)
hour (hr)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Terminal Half-Life (t1/2)25.84 ± 4.2227.23 ± 5.4935.03 ± 4.6133.84 ± 5.39
SecondaryTime for Cmax (Tmax)

Tmax is time for maximum plasma concentration. It is observed directly from data as time of first occurrence of maximum plasma concentration.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Median · hr
Time for Cmax (Tmax)
hrPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Time for Cmax (Tmax)8.00 (6.00 to 12.0)6.00 (6.00 to 6.00)6.00 (2.00 to 6.00)6.00 (2.00 to 8.00)
SecondaryApparent Volunm of Distribution After Oral Dose (Vz/F)

Vz/F is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. It is influenced by the fraction absorbed. It is obtained by dose/(AUCinf•kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.

Time frame:
pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · liter (L)
Apparent Volunm of Distribution After Oral Dose (Vz/F)
liter (L)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Apparent Volunm of Distribution After Oral Dose (Vz/F)2679 ± 183814 ± 363168 ± 262627 ± 29
SecondaryUnbound Vz/F (Vz,u/F)

Vz,u/F is unbound Vz/F, where Vz/F is apparent volume of distribution after oral dose. It is obtained by dose/(AUCinf,u\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Reported as:
Geometric mean · L
Unbound Vz/F (Vz,u/F)
LPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Unbound Vz/F (Vz,u/F)14060 ± 2417730 ± 3614260 ± 3210410 ± 30
SecondaryNumber of Participants With Treatment Emergent Adverse Events

An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

Time frame:
Adverse events were recorded on the Case Report Form from the time the participant had taken at least 1 dose of palbociclib through the participant's last visit.
Reported as:
Number · participant
Number of Participants With Treatment Emergent Adverse Events
participantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Number of Participants With Treatment Emergent Adverse Events2021
SecondaryNumber of Participants With Treatment Emergent Serious Adverse Events

A serious adverse event is any untoward medical occurrence at any dose that resulted in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; or results in congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No).

Time frame:
The active reporting period for serious adverse events began from the time that the participant provided informed consent through and including 28 calendar days after the last administration of palbociclib.
Reported as:
Number · participant
Number of Participants With Treatment Emergent Serious Adverse Events
participantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Number of Participants With Treatment Emergent Serious Adverse Events0010
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.

Time frame:
Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, inclusive of baseline values.
Reported as:
Number · participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
participantsPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)6657
SecondaryNumber of Participants With Physical Examination Test Abnormalities (Change From Prior Visit)

A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.

Time frame:
Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4.
Reported as:
Number · participant
Number of Participants With Physical Examination Test Abnormalities (Change From Prior Visit)
participantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Number of Participants With Physical Examination Test Abnormalities (Change From Prior Visit)0020
SecondaryNumber of Participants With Post Baseline Vital Signs Values Meeting Categorical Summarization Criteria

The number of participants with post baseline vital signs values meeting the following criteria was reported: A. absolute value of supine systolic blood pressure less than (\<) 90 mmHg; B. absolute value of diastolic blood pressure \<50 mmHg; C. absolute value of supine pulse rate \<40 bmp; D. absolute value of supine pulse rate larger than (\>) 120 bmp; E. maximum increase from baseline in supine systolic blood pressure larger than and equal to (\>=) 30 mmHg; F. maximum increase from baseline in supine diastolic blood pressure \>=20 mmHg; G. maximum decrease from baseline in supine systolic blood pressure \>=30 mmHg; and H. maximum decrease from baseline in supine diastolic blood pressure \>=20 mmHg.

Time frame:
Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.
Reported as:
Number · participant
Number of Participants With Post Baseline Vital Signs Values Meeting Categorical Summarization Criteria
participantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
criterion A0100
criterion B0002
criterion C0000
criterion D0000
criterion E0000
criterion F0000
criterion G0011
criterion H0001
SecondaryNumber of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Absolute Values)

Maximum absolute values of post baseline electrocardiogram were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum absolute values of post baseline electrocardiogram meeting the following criteria was reported: (1) PR interval \>=300 msec; (2) QRS complex \>=140 msec; (3) QT interval 450 to \<480 msec; (4) QT interval 480 to \<500 msec; (5) QT interval \>= 500 msec; (6) QTcB 450 to \<480 msec; (7) QTcB 480 to \<500 msec; (8) QTcB \>= 500 msec; (9) QTcF 450 to \<480 msec; (10) QTcF 480 to \<500 msec; and (11) QTcF \>=500 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.

Time frame:
Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.
Reported as:
Number · participant
Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Absolute Values)
participantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
PR interval >=300 msec0000
QRS complex >=140 msec0000
QT interval 450 to <480 msec0114
QT interval 480 to <500 msec0200
QT interval >= 500 msec0000
QTcB 450 to <480 msec0122
QTcB 480 to <500 msec0003
QTcB >= 500 msec0000
QTcF 450 to <480 msec0105
QTcF 480 to <500 msec0000
QTcF >=500 msec0000
SecondaryNumber of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Increase From Baseline)

Maximum increases from baseline for post baseline electrocardiogram values were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum increase from baseline for post baseline electrocardiogram values meeting the following criteria was reported: (1) percent change of PR interval \>=25/50%; (2) percent change of QRS complex \>=50%; (3) QT interval 30 to \<60 msec; (4) QT interval \>= 60 msec; (5) QTcB 30 to \<60 msec; (6) QTcB \>= 60 msec; (7) QTcF 30 to \<60 msec; and (8) QTcF \>= 60 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.

Time frame:
Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.
Reported as:
Number · paticipant
Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Increase From Baseline)
paticipantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
percent change of PR interval >=25/50%0000
percent change of QRS complex >=50%0000
QT interval 30 to <60 msec0002
QT interval >= 60 msec0000
QTcB 30 to <60 msec0001
QTcB >= 60 msec0001
QTcF 30 to <60 msec0000
QTcF >= 60 msec0001
SecondaryNumber of Participants With Concomitant Medications

Treatments taken after the first dose of study treatment were documented as concomitant treatments.

Time frame:
From screening through and including Day 6 for Cohort 1, and from screening through and including Day 9 for Cohorts 2, 3, and 4.
Reported as:
Number · participant
Number of Participants With Concomitant Medications
participantPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
Number of Participants With Concomitant Medications0377

Adverse events

Collected over For adverse event, from the time participant took at least 1 dose of palbociclib through the last visit. For serious adverse event, from the participant provided informed consent through 28 calendar days post last administration of palbociclib.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)—0/7 (0%)2/7 (28.6%)
Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)—0/7 (0%)0/7 (0%)
Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)—1/7 (14.3%)2/7 (28.6%)
Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)—0/7 (0%)1/7 (14.3%)
Most frequent serious events
Most frequent serious events
EventPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
PneumoniaInfections and infestations0/70/71/70/7
Most frequent other events
Most frequent other events
EventPalbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)
NauseaGastrointestinal disorders1/70/70/70/7
VomitingGastrointestinal disorders1/70/70/70/7
Infusion site bruisingGeneral disorders0/70/71/70/7
Infusion site reactionGeneral disorders1/70/70/70/7
HeadacheNervous system disorders0/70/71/71/7
Radial nerve compressionNervous system disorders0/70/71/70/7
DiarrheaGastrointestinal disorders0/70/71/70/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)Total
Mean57.6 ± 2.653.9 ± 5.157.9 ± 4.257 ± 5.356.6 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib 75 mg (Normal Hepatic Function, Cohort 1)Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2)Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3)Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4)Total
Female312410
Male465318
08

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Weston Diagnostics (Ultrasound Facility)
    Orlando, Florida 32825, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Oct 2016, 18 months.

Results were first posted in Jan 2018, 1 year 3 months after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 18 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 8, 2015
StartActual
Mar 31, 2015
Primary completionActual
Oct 9, 2016
CompletionActual
Oct 9, 2016
Results first posted
Jan 24, 2018
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02334800
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 8, 2015
Start date
Mar 31, 2015
Primary completion
Oct 9, 2016
Completion
Oct 9, 2016
Results posted
Jan 24, 2018
Last update
Jan 24, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion